NO20080012L - Fremgangsmater for behandling av hjernetumorer med antistoffer - Google Patents

Fremgangsmater for behandling av hjernetumorer med antistoffer

Info

Publication number
NO20080012L
NO20080012L NO20080012A NO20080012A NO20080012L NO 20080012 L NO20080012 L NO 20080012L NO 20080012 A NO20080012 A NO 20080012A NO 20080012 A NO20080012 A NO 20080012A NO 20080012 L NO20080012 L NO 20080012L
Authority
NO
Norway
Prior art keywords
antibodies
methods
brain tumors
treating brain
treating
Prior art date
Application number
NO20080012A
Other languages
English (en)
Norwegian (no)
Inventor
Kyung Jin Kim
John Laterra
Bachchu Lal
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of NO20080012L publication Critical patent/NO20080012L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20080012A 2005-06-02 2008-01-02 Fremgangsmater for behandling av hjernetumorer med antistoffer NO20080012L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68711805P 2005-06-02 2005-06-02
US75109205P 2005-12-15 2005-12-15
PCT/US2006/021293 WO2006130773A2 (fr) 2005-06-02 2006-06-01 Methodes de traitement des tumeurs du cerveau a l'aide d'anticorps

Publications (1)

Publication Number Publication Date
NO20080012L true NO20080012L (no) 2008-02-20

Family

ID=37482322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080012A NO20080012L (no) 2005-06-02 2008-01-02 Fremgangsmater for behandling av hjernetumorer med antistoffer

Country Status (14)

Country Link
US (2) US20070036797A1 (fr)
EP (1) EP1885400A4 (fr)
JP (2) JP2008545753A (fr)
KR (1) KR20080026562A (fr)
AU (1) AU2006252419B2 (fr)
BR (1) BRPI0611009A2 (fr)
CA (1) CA2607699A1 (fr)
CR (1) CR9512A (fr)
IL (1) IL187318A0 (fr)
MA (1) MA29570B1 (fr)
MX (1) MX2007015056A (fr)
NO (1) NO20080012L (fr)
RU (1) RU2007146986A (fr)
WO (1) WO2006130773A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR20080056167A (ko) 2005-09-26 2008-06-20 메다렉스, 인코포레이티드 씨디70에 대한 인간 모노크로날 항체
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
CA2664738C (fr) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions et procedes permettant de diagnostiquer et de traiter le cancer
JP2010513306A (ja) * 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
MX2010002116A (es) * 2007-08-24 2010-03-26 Novartis Ag Un modulador de nrg1 para el tratamiento de trastornos respiratorios.
WO2009126840A1 (fr) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer
PE20091714A1 (es) * 2008-04-11 2009-11-15 Galaxy Biotech Llc Combinacion del inhibidor hgf y el agonista pten
CA2725873C (fr) * 2008-05-29 2018-05-01 Galaxy Biotech, Llc Anticorps monoclonaux diriges contre un facteur de croissance fibroblastique basique
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
MX2012008958A (es) * 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
EP2588107A1 (fr) * 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
WO2016070051A2 (fr) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
EP3353204B1 (fr) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Anticorps anti-vegf/dll4 bi-spécifique pour le traitement du cancer de l'ovaire résistant au platine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) * 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
EP2392565B1 (fr) * 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
US7964365B2 (en) * 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2009126840A1 (fr) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer

Also Published As

Publication number Publication date
JP2013136580A (ja) 2013-07-11
CR9512A (es) 2008-04-16
US20100221250A1 (en) 2010-09-02
AU2006252419A1 (en) 2006-12-07
CA2607699A1 (fr) 2006-12-07
BRPI0611009A2 (pt) 2010-08-10
WO2006130773A3 (fr) 2009-04-16
MA29570B1 (fr) 2008-06-02
EP1885400A2 (fr) 2008-02-13
MX2007015056A (es) 2008-03-11
WO2006130773A2 (fr) 2006-12-07
RU2007146986A (ru) 2009-06-27
IL187318A0 (en) 2008-04-13
JP2008545753A (ja) 2008-12-18
US20070036797A1 (en) 2007-02-15
EP1885400A4 (fr) 2011-01-26
KR20080026562A (ko) 2008-03-25
AU2006252419B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
NO20080012L (no) Fremgangsmater for behandling av hjernetumorer med antistoffer
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
NO20056027L (no) Surrogat terapeutisk endepunkt for anti-CTLA-4 basert immunoterapi av sykdom
NO20083066L (no) Antistoffmolekyler med spesifisitet for human-IL-6
UA109633C2 (uk) Антитіло людини проти тканинного фактора
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
WO2007109742A3 (fr) Methodes d'humanisation d'anticorps et anticorps humanises ainsi obtenus
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
NO20066075L (no) Antistofflegemiddelkonjugater og fremgangsmater
WO2010019702A3 (fr) Agents de liaison à ddr1 et leurs méthodes d'utilisation
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
ATE516819T1 (de) Verfahren zur behandlung von b-zell-bedingtem krebs
MX2008012023A (es) Metodos para prevenir y tratar enfermedades amiloidogenicas.
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
EP2670435A1 (fr) Utilisation d'un anticorps monoclonal anti-dkk1 pour le traitement du cancer du foie
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2008070090A3 (fr) Compositions et procédés pour diagnostiquer et traiter un cancer
ATE534386T1 (de) Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
WO2007007152A3 (fr) Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
WO2007007160A3 (fr) Anticorps anti-madcam servant a traiter la fievre

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application